gdc

April 2017 Vol 3 No 2

Informed Patient? Don’t Bet On It
Survivorship
Dr. Sekeres and Dr. Gilligan examine the hidden problem of uniformed patients, and offer tips for patients to better communicate with and understand their doctors.
Maryann Wahmann: When Cancer Runs in the Family
Hero of HopeNeuroendocrine Tumors
Maryann Wahmann is the 2016 Hero of Hope Patient Award winner. Over 7 years, she had 7 colonoscopies, 7 endoscopies, and several wrong diagnoses before being diagnosed with carcinoid cancer, a type of neuroendocrine tumor (NET).
Finding Positive Spots in My Multiple Myeloma Journey
Multiple Myeloma
Saying a few good words about cancer may seem a daunting task. However, lately it has occurred to me that my journey with cancer has some bright spots. It all began on March 17, 2014. The day you learn you might have cancer is a date you never forget.
Kisqali a New First-Line Treatment for Patients with Advanced Breast Cancer
FDA Approvals, News & UpdatesNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Keytruda Now Available for Patients with Relapsed Classical Hodgkin Lymphoma
FDA Approvals, News & UpdatesNewsworthy
In March 2017, the FDA approved Keytruda (pembrolizumab), anti-PD-1 immunotherapy, for the treatment of patients with classical Hodgkin lymphoma who are not responding to other therapy or whose disease (relapsed) returned after 3 or more therapies. Keytruda was previously approved for several cancers.
Revlimid Approved for Maintenance Therapy in Patients with Multiple Myeloma After Transplant
FDA Approvals, News & UpdatesMultiple MyelomaNewsworthy
In February 2017, the FDA approved the oral drug Revlimid (lenalidomide) for maintenance (continuing) therapy for patients with multiple myeloma who had autologous hematopoietic stem-cell transplant. Revlimid was previously approved for multiple myeloma and for other types of cancer.
Imbruvica First Non-Chemotherapy Drug Approved for Patients with Marginal Zone Lymphoma
FDA Approvals, News & UpdatesNewsworthy
In January 2017, the FDA approved Imbruvica (ibrutinib) for the treatment of patients with marginal zone lymphoma who need systemic therapy and have received at least 1 previous anti-CD20-based therapy.
Opdivo a New Treatment Option for Patients with Advanced or Metastatic Bladder Cancer
FDA Approvals, News & UpdatesNewsworthy
In February 2017, the FDA approved Opdivo (nivolumab), anti-PD-1 immunotherapy, for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Rubraca a New Oral Treatment Approved for Patients with Advanced Ovarian Cancer
FDA Approvals, News & UpdatesNewsworthy
In December 2016, the FDA approved Rubraca (rucaparib), a new oral PARP inhibitor, for the treatment of advanced ovarian cancer with a BRCA mutation (alteration) in patients who had received at least 2 chemotherapies.
Page 2 of 3
Results 11 - 20 of 21

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest